Gufic Bio – Q2 and H1 highlights –
Q2 financials –
Sales – 215 vs 175 cr
EBITDA – 40 vs 33 cr ( margins at 18.5 vs 19 pc )
PAT – 23 vs 20 cr
Domestic business – has 8 business units with a field force of > 1000 ppl. Products cover 15 therapeutic areas
CMO business – 50+ products, one of the largest lyophillization capacities in the world
APIs – specialises in anesthetics, Anti-Fungals, Anti-Biotics
International business – exports to over 20 countries
Current facilities –
Unit -1 Navsari – makes Ampoules, Ointments, Lotions, Syrups, Lyophilised powders, PFS (pre filled syringes)
Unit -2 Navsari – Lyophilised powders, PFS
Gufic Belgaum – Oral Solids – natural products
Upcoming facilities –
Unit – 3 Indore – Lyophilization, PFS
Completion by Sep 23, revenue contribution from Q3
Penem Block – Dedicated facility for Carbapenems (lyophilised, oral solids, dual chamber bags, dry powder)
Botulinum Toxin facility at Navsari – to make Botulinum toxin API and formulations in partnership with Prime Bio, USA ( used in Pain management , Derma and Neurology )
About 50 pc of company’s revenues come from Domestic business. Critical Care + Infertility care form about 70 pc of domestic business ( 45 + 25 pc each )
About 30 pc sales are from CMO business with 10 pc sales each from Intl and API business
Company has received DGCI approval for launch of Delbavancin ( used in acute skin and bacterial infections ) in India. Seeing good traction
Company sells to 50 pc of all IVF clinics in India
Company’s SPARSH division – has been set up to do the business like a wholesaler of 92 + molecules based Injectables to over 1000 hospitals in India. Currently, this division has a field force of about 40 ppl and is doing a business of about 3-4 cr/month. Expecting a good ramp up in the Sparsh division
Also launched SeraSeal under the SPARSH division. It’s an innovative homeostatic agent aimed at stopping bleeding on contact. Finding wide acceptance
Dydrogesterone ( infertility product ) – grew 20 pc QoQ in Q2. Sales expected to double in this FY
Company conducting trials for its own HMG ( human menopausal Gonadotropin ). It increases the success rate of IVF cycles. Trials are on vs established international player’s product
Q2 growth mainly led by Domestic mkt that’s doing much better
Rs 100 cr were raised by the company via preferential allotment. The same shall be used for Debt repayment
Deterioration in working capital cycle due – CMO business pick up and launch of SPARSH division where the payments are received from MNCs / Hospitals only after 90-120 days
Disc: holding, biased, not SEBI registered
| Subscribe To Our Free Newsletter |
